Thank you for the question.
Thank you, Hilary.
In regard to the two approved products that Ms. Geller referred to as Sativex and Cesamet, I'll just situate things. As I'm sure everyone knows there's a very rigorous process in place for the approval of drug products in Canada under the Food and Drugs Act around safety, efficacy, and quality. Specifically, the two that were mentioned were Sativex and Cesamet.
Sativex is a cannabis-based medicine and it really is indicated quite specifically. It contains both THC and cannabidiol, and it really is indicated for specific treatment, an adjunctive treatment for symptomatic relief of neuropathic pain for adults who suffer from multiple sclerosis. So that is what it is specifically indicated for.
In the case of Cesamet, it is a synthetic cannabinoid, therefore it is manufactured synthetically and it's administered orally. It has antiemetic properties, which have been found to be of value in the management of some patients who are dealing with nausea and vomiting, who are undergoing cancer chemotherapy. Those are two examples of the only two drug approvals that our colleagues in the health products and food branch have approved and given notices of compliance and issued drug identification numbers to. But again, when we speak about the benefits, clearly the indications of those two drugs are quite specific to certain conditions.